624
Views
9
CrossRef citations to date
0
Altmetric
Clinical Immunology

Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria

, , , , , , , , , & show all
Pages 35-39 | Received 20 Sep 2017, Accepted 19 Oct 2017, Published online: 10 Nov 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Eugenio Provenzano & Pietro Morrone. (2018) Effective treatment with omalizumab of a patient with spontaneous chronic urticaria and eosinophilic esophagitis. Journal of Dermatological Treatment 29:sup4, pages 5-7.
Read now
Jonathan A. Bernstein, Abhishek Kavati, Michael D. Tharp, Benjamin Ortiz, Karen MacDonald, Kris Denhaerynck & Ivo Abraham. (2018) Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence. Expert Opinion on Biological Therapy 18:4, pages 425-448.
Read now

Articles from other publishers (7)

Christina Yu. Popova, Victoria A. Zaborova, Vladislav V. Kurshev, Elena V. Kovalkova, Sofia A. Serdotetskova, Daria S. Fomina & Elena Yu. Borzova. (2024) Clinical predictors of antihistamine resistance in patients with chronic spontaneous urticaria. Russian Journal of Allergy 20:4, pages 402-414.
Crossref
Christine J. Rubeiz, Ricardo Asero, Stephen Betschel, Timothy Craig, Anete Grumach, Michihiro Hide, David Lang, Michael Levin, Hilary Longhurst, Eli Magan, Marcus Maurer, Romi Saini, Gordon Sussman, Elias Toubi, Dinh Nguyen Van, Torsten Zuberier & Jonathan A. Bernstein. (2024) Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria. World Allergy Organization Journal 17:1, pages 100858.
Crossref
Fatma TUNCEZ AKYUREK, Nihal SARİ, Gülcan SAYLAM KURTİPEK, Gözde ULUTAŞ DEMİRBAŞ, Emre ZEKEY, Mehmet AKYÜREK & Neriman AKDAM. (2021) Turkey Urticaria Diagnosis and Treatment Guide based; Distribution of Chronic Urticaria Patients Treated in Our Clinic According to Step TherapyTürkiye Ürtiker Tanı ve Tedavi Kılavuzu Baz Alınarak Kliniğimizde Tedavi Edilen Kronik Ürtikerli Hastaların Basamak Tedavisine Göre Dağılımı. Journal of Contemporary Medicine 11:1, pages 110-112.
Crossref
Amanda P. McIntyre, Ravi K. Viswanathan, Mark H. Moss & Sameer K. Mathur. (2020) Real-world dosing of omalizumab for chronic spontaneous urticaria. Annals of Allergy, Asthma & Immunology 124:2, pages 211-212.
Crossref
H. Lapeere, M. Baeck, A. Stockman, V. Sabato, M. Grosber, M. Moutschen, J. Lambert, L. Vandebuerie, L. de Montjoye, H. Rabijns, K. Allewaert & R. Schrijvers. (2019) A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real‐world study in Belgium. Journal of the European Academy of Dermatology and Venereology 34:1, pages 127-134.
Crossref
Ivan Cherrez-Ojeda, Marcus Maurer, Jonathan A. Bernstein, Emanuel Vanegas, Miguel Felix, German D. Ramon, Luis Felipe Ensina, José Ignacio Larco Sousa, Edgar Emilio Matos Benavides, R. Cardona Villa, P. Latour Staffeld, Blanca María Morfin-Maciel, Jose Mori, Paul Wilches C, Valeria L. Mata & Annia Cherrez. (2019) Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America. World Allergy Organization Journal 12:2, pages 100011.
Crossref
Désirée E. S. Larenas-Linnemann, Claudio A. S. Parisi, Carla Ritchie, Ricardo Cardona-Villa, Ivan Cherrez-Ojeda, Annia Cherrez, Luis Felipe Ensina, Elizabeth Garcia, Iris V. Medina, Mónica Rodríguez-González & Jorge Mario Sánchez Caraballo. (2018) Update on Omalizumab for Urticaria: What’s New in the Literature from Mechanisms to Clinic. Current Allergy and Asthma Reports 18:5.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.